Loading clinical trials...
Loading clinical trials...
Evaluating the Safety and Effectiveness of Cemiplimab in Combination With Platinum-Doublet Chemotherapy by Demographic Characteristics in First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Multi-Database Real World Evidence Study in US Patients
Conditions
Interventions
REGN2810
Platinum-doublet chemotherapy
Locations
1
United States
Regeneron Research Facility
Tarrytown, New York, United States
Start Date
February 21, 2024
Primary Completion Date
March 31, 2027
Completion Date
June 23, 2027
Last Updated
August 27, 2025
NCT06731413
NCT07356544
NCT06956001
NCT06706076
NCT07371663
NCT07222566
Lead Sponsor
Regeneron Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions